PulseAugur
EN
LIVE 05:23:51
中文(ZH) 创新药板块向好趋势不改,优质资产已进入配置区间

GPT-5.6 reportedly released, Codex discontinued, Claude faces pressure

A new AI model, GPT-5.6, has reportedly been released, while Codex appears to be discontinued and Claude is facing competitive pressure. This development comes amidst broader market shifts, including a dip in the ChiNext index and significant capital inflows into Hong Kong markets. The news also touches upon unrelated topics such as the performance of fuel vehicles and the IPO plans of CXMT. AI

IMPACT The emergence of GPT-5.6 and the competitive landscape for models like Claude could signal shifts in AI capabilities and market dynamics.

RANK_REASON The cluster discusses a purported new AI model release (GPT-5.6) and the status of others (Codex, Claude), but lacks direct confirmation from the primary labs, framing it as market commentary.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

GPT-5.6 reportedly released, Codex discontinued, Claude faces pressure

COVERAGE [2]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    创业板指翻绿

    36氪获悉,创业板指翻绿,此前一度涨超1%。

  2. 36氪 (36Kr) TIER_1 中文(ZH) ·

    The upward trend of the innovative drug sector remains unchanged, and high-quality assets have entered the allocation range.

    近期,A股创新药板块在经历一轮强劲反弹后遭遇短期调整,7月9日企稳回升。本轮行情由科技板块资金高低切换与政策面利好共同驱动,港股创新药同步走强,板块回购潮持续升温。产业层面,中国创新药出海延续高增态势,BD(商务拓展)合作从传统单一授权向共同开发、利润共享模式升级,CXO(医药研发生产外包服务组织)产业链需求回暖和供给出清并行,盈利修复预期增强。分析人士认为,创新药板块核心关注点正从“能否出海”转向“商业化利润能否兑现”,优质创新药企估值已进入具备吸引力的配置区间,短期波动不改中长期向好趋势,建议把握逢低配置机会。(中证报)